Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers

Phase I Clinical Study of Single-center, Randomized, Double-blind, Single-dose, Parallel Comparison of the Pharmacokinetics and Safety of Ramucirumab Injection and Cyramza® in Healthy Male Volunteers

Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®.

Study Overview

• Status: Completed
• Conditions: Gastric Cancer; Non-small Cell Lung Cancer; Colo-rectal Cancer
• Intervention / Treatment: Drug: Ramucirumab Injection; Drug: Ramucirumab Injection [Cyramza]

• Study Type: Interventional
• Enrollment (Actual): 88
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Jilin
    • Changchun, Jilin, China, 130021
      • Affiliated Hospital of Changchun University of Traditional Chinese Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Sign informed consent form before the study and fully understand the study content, process and possible adverse reactions;
• Be able to complete the study according to the requirements of the test plan;
• Male subjects aged 18-65 years (included);
• The subject should weigh at least 50kg. Body mass index (BMI) = weight (kg)/ height2(m2), BMI in the range of 19 to 26 (included);
• Health status: no mental abnormality, no medical history of abnormal cardiovascular system, nervous system, respiratory system, digestive system, urinary system, endocrine system and metabolism;
• Normal or abnormal vital signs, physical examination, laboratory examination, electrocardiogram and imaging examination with no clinical significance;
• Have no pregnancy plan and voluntarily take effective contraception measures from 2 weeks before the study drug administration to at least 6 months after the last dose.

Exclusion Criteria:

• Have a history of neuropsychiatric system, respiratory system, cardiovascular system, digestive system, hemolymph system, liver and kidney insufficiency, endocrine system, skeletal and musculoskeletal system disease or other diseases, and the investigators judge that this history may affect drug metabolism or safety;
• Known allergic to Ramucirumab or its excipients; Known history of allergic diseases or allergic constitution;
• History of hypertension or abnormal blood pressure at screening/baseline measurement (systolic blood pressure (SBP) > 140 mmHg, and/or diastolic blood pressure (DBP) >90 mmHg, confirmed by one repeat measurement on the same day);
• A history of clinically significant albuminuria (urine routine examination, albuminuria 2+ and above) or albuminuria as assessed by the investigator;
• Had received treatment of Ramucirumab or VEGFR2 receptor antagonist, or other antibody or protein drugs that target VEGFR2 receptor;
• Had received any live viral vaccine within 2 months prior to study drug infusion, or required vaccination between the screening period and the end of the study, had used any monoclonal antibody or biologic drug within 12 months prior to study drug administration, or planned to receive any monoclonal antibody or biologic drug within 12 months after study drug administration;
• had unhealed wound ulcers or fractures, or had undergone major surgery within 3 months prior to study drug infusion or expected to undergo major surgery during the study period or within 2 months after study completion;
• had taken any prescription drugs, over-the-counter drugs, any vitamin products, or herbs within 14 days prior to use of the study drug;
• Patients with abnormal examinations and clinical significance during the screening period;
• Blood donation or significant blood loss within 3 months prior to use of the study drug (>450 mL);
• Have taken the study drug or participated in any clinical trial of the drug within 3 months prior to the use of the study drug;
• Smokers who smoked more than 5 cigarettes a day in the 3 months before the test;
• Test positive for alcohol or have a history of alcohol abuse (14 units of alcohol per week: 1 unit =360 mL of beer or 45 mL of 40% spirits or 150 mL of wine);
• Test positive for drugs or have a history of drug abuse in the past five years or have used drugs in the three months prior to the test;
• Hepatitis (including hepatitis B and C), AIDS, syphilis positive screening;
• Patients with difficulty in venous blood collection or who cannot tolerate venipuncture;
• Unable or unable to comply with ward management regulations, poor compliance during the study, or unable to follow protocol requirements to complete the study;
• Subjects unable to complete the experiment due to personal reasons;
• Conditions considered unsuitable for inclusion by other researchers.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ramucirumab injection; 8mg/kg, Single intravenous infusion	Drug: Ramucirumab Injection; Ramucirumab injection biosimilar products manufactured by Chia Tai Tianqing Pharmaceutical,
Active Comparator: Cyramza; 8mg/kg, Single intravenous infusion	Drug: Ramucirumab Injection [Cyramza]; Ramucirumab Injection is a humanized monoclonal antibody based on the human immunoglobulin G1(IgG1) skeleton sequence, developed by Eli Lilly Co., the bran name is Cyramza. Ramucirumab is a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist that specifically binds to VEGF receptor 2 and blocks VEGFR ligand, VEGF-A, VEGF-C, and VEGF-D binding to the receptor. As a result, Ramucirumab inhibits ligand-stimulated VEGF receptor 2 activation, thereby inhibiting ligand-induced proliferation, and human endothelial cell migration. Ramucirumab inhibits angiogenesis, thereby blocking the tumor's blood vessel supply.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under drug concentration - time curve (AUC0-t)	Area under the curve from zero to the lowest detectable blood drug concentration.	Within 60 minutes before administration to 1680 hours after administration.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under drug concentration - time curve (AUC0-∞)	The area under the curve extrapolating from zero to infinity.	Within 60 minutes before administration to 1680 hours after administration.
Peak concentration (Cmax)	Peak maximum plasma drug concentration	Within 60 minutes before administration to 1680 hours after administration.
Peak concentration time (Tmax)	Time to reach maximum plasma concentration after dosing	Within 60 minutes before administration to 1680 hours after administration.
Clearance rate (CL)	Percentage of the organ-scavenging drugs that eliminated by the body	Within 60 minutes before administration to 1680 hours after administration.
Half-life (T1/2)	The time it takes for serum drug concentrations to drop by half	Within 60 minutes before administration to 1680 hours after administration.
Apparent volume of distribution (Vd)	Apparent volume of distribution after administration	Within 60 minutes before administration to 1680 hours after administration.

Collaborators and Investigators

• Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): November 4, 2019
• Primary Completion (Actual): February 18, 2020
• Study Completion (Actual): February 18, 2020

Study Registration Dates

• First Submitted: March 24, 2023
• First Submitted That Met QC Criteria: March 24, 2023
• First Posted (Actual): April 5, 2023

Study Record Updates

• Last Update Posted (Actual): April 5, 2023
• Last Update Submitted That Met QC Criteria: March 24, 2023
• Last Verified: October 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Diseases; Intestinal Neoplasms; Rectal Diseases; Lung Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Rectal Neoplasms; Physiological Effects of Drugs; Antineoplastic Agents; Immunologic Factors; Ramucirumab; Antibodies, Monoclonal
• Other Study ID Numbers: ZDTQ-2019-LMLDK

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No